Next, we tested short-term/acute intervention on S100A10 or S100A11 for potential beneficial effects on steatosis reduction in an early phase by downregulating for only 1 month either S100A10 or S100A11 at 4 months of age (Fig. 2I). The gene discussed is S100A10; the disease is steatosis.